HCA Warning, Leqembi, FTC, ICER

MarcusWelcome to the Access Brief — your daily briefing on what's moving in HEOR, HTA, and market access. I'm Marcus, and it's great to have you with us today.

SaraAnd I'm Sara. Always good to be here — and I'll say, I've had today's topics circled since this morning, especially the HCA and Leqembi stories.

MarcusSame here. We're looking at HCA's profit warning and what it signals for US healthcare access. Then the subcutaneous Leqembi approval and its HEOR implications. Next, the FTC settlement with CVS Caremark over insulin pricing. And finally, ICER's expansion of scientific advice.

SaraThat second one on Leqembi is particularly interesting to me — the value narrative for Alzheimer's therapies is still evolving, and the subcutaneous formulation adds a new layer.

MarcusExactly. Let's get into it.

MarcusHCA's recent profit warning has sent ripples through the market. They're citing access erosion and reimbursement challenges as key factors. This isn't just a financial blip; it's a symptom of broader system pressures on hospital margins, especially for innovative therapies.

SaraThat's a fair point, Marcus. But from a payer perspective, I wonder if the full picture is about the shifting cost burden. Hospitals are absorbing more of the risk for high-cost drugs, and when payers tighten reimbursement, it hits them directly. The budget impact here is significant.

MarcusAnd what's striking is that this isn't isolated. We're seeing similar patterns in other large health systems. The question is whether this is a temporary adjustment or a structural shift in how value is reimbursed.

SaraI'd frame it as a structural shift. The rise of high-cost oncology and rare disease therapies, coupled with increasing payer scrutiny on cost-effectiveness, is creating a perfect storm. Hospitals are caught in the middle.

MarcusThat connects to something I keep coming back to: the tension between innovation and system sustainability. How do we balance rewarding breakthroughs with keeping the system solvent?

SaraExactly. And the patient perspective is critical here — if hospitals cut services or access to innovative drugs, it's the patients who suffer. That's the access angle we can't ignore.

MarcusThis is one of those stories where the financials are just the tip of the iceberg. The real implications are for patient access and the long-term viability of delivering innovative care.

SaraThe part that gives me pause is the lack of a clear solution. We need better mechanisms to share risk between manufacturers, payers, and providers. Otherwise, the system will continue to fracture.

MarcusAbsolutely. And until we address that, these profit warnings will become more common. The HEOR community has a role in modeling those risk-sharing arrangements.

MarcusThe FDA's approval of subcutaneous Leqembi is a significant development for Alzheimer's treatment. It addresses a key barrier — the burden of intravenous infusions — which could improve patient adherence and quality of life. From an HEOR perspective, this is about expanding the value proposition beyond clinical efficacy.

SaraThat's one read, but I'd push back slightly. The core value question remains unchanged: is the incremental benefit worth the price? And now we have a new formulation that might increase the eligible population. The budget impact could be substantial.

MarcusThat's fair. The subcutaneous route does open the door to broader use, but we need to see the real-world evidence on adherence and outcomes. The HEOR community will be watching for studies that capture that.

SaraAnd from the payer side, the challenge is demonstrating that the improved administration translates to meaningful health gains that justify the cost. Otherwise, it's just a more convenient delivery of a high-priced drug with modest efficacy.

MarcusWhat strikes me is that this could set a precedent for other neurodegenerative therapies. If payers accept a higher threshold for Alzheimer's, it might open doors for similar high-cost, high-need treatments.

SaraBut that's a double-edged sword. If we set the bar too high for cost-effectiveness, we risk crowding out other innovations. The opportunity cost is real. Payers will be looking closely at the ICER assessment for this one.

MarcusThis is one of those stories where the innovation is clear, but the value narrative is still being written. The HEOR community has a role in shaping that narrative.

MarcusThe FTC settlement with CVS Caremark over insulin pricing is a landmark moment. It addresses the practice of spread pricing, where PBMs mark up drug prices, and aims to increase transparency. For market access, this signals a shift toward more competitive pricing in the insulin market.

SaraThat's one way to see it, but I'd frame it slightly differently. The real story here is about power dynamics in the supply chain. By forcing PBMs to pass rebates directly to patients, the settlement could lower out-of-pocket costs, but it doesn't address the list price inflation that drives the system.

MarcusThat's a fair point. The settlement targets the middlemen, but the root cause — the high list prices of insulin — remains. The HEOR question is whether this will lead to sustainable access or just a rearrangement of costs.

SaraExactly. And from a payer perspective, the budget impact is uncertain. If rebates are passed through, it might reduce patient assistance programs, which could increase overall system costs. The long-term implications are still unclear.

MarcusWhat's interesting is the precedent this sets for other high-cost drugs. If the FTC can intervene in insulin, what about oncology or gene therapies? It could signal a new era of antitrust scrutiny in pharmaceutical pricing.

SaraThat's the thread I'm watching. How this settlement will influence future negotiations and whether it leads to more competitive pricing or just more regulation. The patient benefit is real, but the system impact is complex.

MarcusICER's expansion of scientific advice to include early-phase development is a game-changer. It allows companies to get real-time feedback on evidence generation strategies, potentially reducing late-stage failures. For HEOR, this is about de-risking development and aligning evidence with payer expectations.

SaraThat's the industry perspective, but I wonder if that's the full picture. Payers are already stretched thin, and this could create a bottleneck. The question is whether early-phase advice will actually lead to more efficient development or just more administrative burden.

MarcusI see your point. The capacity is a real concern. But the alternative is companies developing in a vacuum, leading to evidence that doesn't meet payer needs. This could be a way to align incentives.

SaraAnd what about the cost? Companies will have to invest in this early engagement, which might deter smaller players. The opportunity cost for payers is significant too — they're diverting resources from appraisals to early advice.

MarcusThat's a fair challenge. But I'd argue that the long-term payoff is worth it. If we get better evidence earlier, it could reduce the number of technologies that fail at HTA, saving everyone time and money.

SaraThat's true, but the proof will be in the pudding. We need to see if this actually leads to higher rates of positive recommendations. Otherwise, it's just another layer in a complex system.

MarcusThis is one of those stories where the intent is good, but the execution will determine the impact. The HEOR community will be watching closely.

SaraA lot to think about today. I'll be watching how the HCA profit warning signals ripple through other health systems and whether it leads to policy changes.

MarcusSame — and for me the thread running through today is the tension between innovation and system sustainability. We're seeing it in hospitals, in drug pricing, and in evidence generation.

SaraThanks so much for listening — really glad you're here with us.

MarcusWe'll be back tomorrow. Show notes and transcripts at outcomes-analytica.no. See you then.

SaraThanks for listening — see you tomorrow.

MarcusBack tomorrow on Access Brief. Show notes at outcomes-analytica.no.